Activating Compound | Comment | Organism | Structure |
---|---|---|---|
fragment X | profibrinolytic effect with plasmin. Rates of plasmin formation increase with increasing fragment X concentrations. Plasmin degrades clots containing fragment X more rapidly than fibrin clots | Homo sapiens |
Application | Comment | Organism |
---|---|---|
medicine | plasmin can impair hemostasis by partially degrading fibrinogen to fragment X, a product that retains clottability but forms clots with reduced tensile strength that stimulate plasminogen activation by tissue-type plasminogen activator more than fibrin clots. Attenuation of thrombolytic therapy-induced fragment X formation may reduce the risk of bleeding | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
alpha2-antiplasmin | inhibitory activity is neutralized by addition of the antibody against alpha2-antiplasmin | Homo sapiens | |
fibrinogen | competitive inhibitor of plasmin chromogenic activity | Homo sapiens | |
fragment X | competitive inhibitor of plasmin chromogenic activity | Homo sapiens | |
VFK-CMK | - |
Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
plasma | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
Fibrin + H2O | - |
Homo sapiens | ? | - |
? | |
fibrinogen + H2O | fragment X generated by limited plasmin digestion of fibrinogen | Homo sapiens | fragment X | - |
? | |
H-D-Val-Leu-Lys-p-nitroaniline dihydrochloride + H2O | - |
Homo sapiens | ? | - |
? |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.0038 | - |
fibrinogen | - |
Homo sapiens | |
0.0095 | - |
fragment X | - |
Homo sapiens |